Hanmi Pharmaceutical Company Limited $128940.KS
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS8
PHASE 3 / 2-33
RECRUITING5
READOUTS ≤12 MONTHS5
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| HM15136 NCT04732416 |
P2 | Active, not recruiting | Congenital Hyperinsulinism | 17 | 2026-06-16 (+42 mo) |
| HM15275 NCT07205900 |
P2 | Active, not recruiting | Obese; Obesity | 267 | 2027-01 |
| HIP2602 + HPP2602-2 NCT07899073 |
P3 | Recruiting | Erectile Dysfunction | 225 | 2027-09 |
| HM15275 NCT07527650 |
P2 | Recruiting | Type 2 Diabetes Mellitus; T2DM | 180 | 2027-10 |
| HCP1803-3 NCT07660796 |
P3 | Not yet recruiting | Hypertension | 256 | 2027-10-30 |
| HM11260C NCT07379333 |
P3 | Recruiting | Type 2 Diabetes | 118 | 2027-11 |
| HM15912 Active NCT04775706 |
P2 | Recruiting | Short Bowel Syndrome | 18 | 2027-12 (+48 mo) |
| Belvarafenib NCT07449754 |
P2 | Recruiting | Advanced or Metastatic Melanoma | 45 | 2029-09 |